Journal cover. (Molecules)
How might the novel coronavirus be prevented from entering a host cell in an effort to thwart infection? A team of biomedical scientists has made a discovery that points to a solution.
The scientists, led by Maurizio Pellecchia in the School of Medicine at the University of California, Riverside, report in the journal Molecules that two proteases — enzymes that break down proteins — located on the surface of host cells and responsible for processing viral entry could be inhibited. Such protease inhibition would prevent SARS-CoV2, the coronavirus responsible for COVID-19, from invading the host cell.
The research is featured as the cover story of the journal (Volume 25, Issue 10).
The outer surface of coronaviruses contains a critical protein called spike glycoprotein, or S-glycoprotein. Responsible for giving the coronavirus its typical crown shape, the S-glycoprotein is essential for the entry of viral particles into host cells. Host cell proteases, however, must first process or cut this viral surface protein to allow the virus to enter the cells.
Pellecchia’s lab and others have recognized that in addition to a previously identified protease called TMPRSS2, the new SARS-CoV2 coronavirus could also be processed by an additional human protease, called furin, for viral entry.
“The use of the host protease furin for processing is a common mechanism of cell entry by both viral fusion proteins and certain bacterial toxins,” said Pellecchia, a professor of biomedical sciences, who led the research team. “SARS-CoV2 uses this mechanism also. The nature of the ‘proteolytic cleavage’ in its S-glycoprotein can determine whether this virus can be transmitted across species, for example from bats or camels to humans.”
A fusion protein combines the attributes of more than one protein. Proteolytic cleavage refers to the process of breaking the peptide bonds between amino acids in a protein, which results in cutting the protein.
The coronavirus S-glycoprotein contains three cleavage sites that human host proteases process. The exact nature and sequence of these cleavage sites, and their respective processing proteases, can determine the level of pathogenicity and whether the virus can cross species.
Spotlight on inhibitors
Pellecchia explained that the anthrax toxin, similar to SARS-CoV2, requires processing by human furin to infect macrophages, a type of white blood cell. Using anthrax toxin as model system, his team found an inhibitor of both TMPRSS2 and furin in cellular and animal models can efficiently suppress cell entry by the toxin.
A clinical trial with COVID-19 patients recently began using the TMPRSS2 inhibitor camostat.
“We found, however, that camostat is a poor furin inhibitor,” Pellecchia said. “Our current study, therefore, calls for the development of additional protease inhibitors or inhibitor-cocktails that can simultaneously target both TMPRSS2 and furin and suppress SARS-CoV2 from entering the host cell.”
Pellecchia added that until now the presence of a furin cleavage site in SARS-CoV2 had been linked to increased pathogenicity. But genetic elimination of furin in cellular laboratory studies failed to stop viral entry, suggesting TMPRSS2 remains the most relevant protease.
Using peptide sequences from SARS-CoV2 S-glycoprotein, however, his team has now demonstrated the new mutations in this coronavirus strain resulted in efficient and increased processing of viral entry by furin and TMPRSS2.
“In other words, SARS-CoV2, unlike other less pathogenic strains, can more efficiently use both proteases, TMPRSS2 and furin, to start the invasion of host cells,” Pellecchia said. “While TMPRSS2 is more abundant in the lungs, furin is expressed in other organs, perhaps explaining why SARS-CoV2 is capable of invading and damaging multiple organs.”
Pellecchia’s lab has already identified potent and effective preclinical inhibitors of furin and demonstrated these inhibitors could be developed as potential COVID-19 therapeutics, perhaps in combination with drugs such as camostat, the TMPRSS2 inhibitor.
“We are seeking additional funding to pursue the design and development of dual inhibitors that can simultaneously target both TMPRSS2 and furin,” Pellecchia said. “The funding would allow us to explore new possible effective therapeutics against COVID-19 and support studies that could have far reaching applications to ward off possible future pandemics resulting from similar activating mutations in other viral strains.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Otero health director on how to break down the bridges of coronavirus spreadon November 12, 2020 at 1:09 pm
Otero Health Director Rick Ritter urges residents to do their part to reduce the spread of COVID-19 this Nov., before a Stay at Home order is issued.
- How WHO is working to track down the animal reservoir of the SARS-CoV-2 viruson November 6, 2020 at 4:21 am
The introduction of a new virus to the human population is one of the greatest mysteries an epidemiologist can hope to unravel. Some of the most common and deadliest human diseases are caused by ...
- NERSC Supports COVID-19 Pandemic Responseon November 2, 2020 at 10:57 am
Currently, NERSC is hosting 20 projects covering a wide swath of COVID-19 research, including explorations into FDA-approved drug repurposing, molecular simulations, explorations of resilience, ...
- Coronavirus may dull the body's pain receptors, helping the unsuspecting spread it, study sayson October 26, 2020 at 8:11 pm
"Depending on the person someone could become infected with SARS-CoV2 and never exhibit symptoms ... that lead to anosmia and pain or pain suppression are through similar kinds of receptors ...
- Coronavirus may dull the body's pain receptors, helping the unsuspecting spread it, study sayson October 26, 2020 at 4:14 pm
"Depending on the person someone could become infected with SARS-CoV2 and never exhibit symptoms but still ... "I think the pathways that lead to anosmia and pain or pain suppression are through ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Effective therapeutics against COVID-19
- Acuitas Therapeutics: The Canadian technology that the Pfizer and BioNTech COVID-19 vaccine 'can't work without'on November 10, 2020 at 1:26 pm
Canadian company Acuitas Therapeutics is behind a core component of the Pfizer and BioNTech COVID-19 vaccine development.
- Study may help develop effective drugs against COVID-19on November 5, 2020 at 9:19 pm
Scientists at the University of Cambridge, in collaboration with Justus-Liebig University, Germany, have uncovered how the genome of SARS-CoV-2 - the coronavirus that causes COVID-19 - uses genome ...
- MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENTon November 4, 2020 at 4:12 am
COVID-19 VaccinesAGOURA HILLS, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud (INS), the ...
- Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccineon November 2, 2020 at 6:16 am
PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial ...
- Eli Lilly's Bamlanivimab Phase 2 Study Data Shows Treatment May Be Effective Against COVID-19on October 28, 2020 at 3:14 pm
Data from the BLAZE-1 study show bamlanivimab may be effective in ... antibodies as therapeutics for people recently diagnosed with mild to moderate COVID-19, particularly high-risk patients ...